Integral Derivatives’s AstraZeneca AZN Stock Holding History

Integral Derivatives’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,750	Closed	-$815K	–	693
2017 Q4	$815K	Buy	11,750 +3,450	+42%	+$233K	0.02%	552
2017 Q3	$562K	Sell	8,300 -50,250	-86%	-$3.17M	0.01%	689
2017 Q2	$3.99M	Buy	58,550 +34,850	+147%	+$2.28M	0.08%	146
2017 Q1	$1.48M	Buy	23,700 +16,050	+210%	+$934K	0.03%	407
2016 Q4	$418K	Buy	7,650 +600	+9%	+$34.1K	0.01%	783
2016 Q3	$463K	Buy	7,050 +1,350	+24%	+$88.2K	0.01%	657
2016 Q2	$344K	Buy	+5,700	New	+$331K	0.01%	701
2015 Q4	–	Sell	-7,700	Closed	-$490K	–	1064
2015 Q3	$490K	Buy	+7,700	New	+$507K	0.01%	714
2015 Q2	–	Sell	-10,000	Closed	-$684K	–	1099
2015 Q1	$684K	Sell	10,000 -64,800	-87%	-$4.5M	0.01%	615
2014 Q4	$5.26M	Buy	74,800 +29,100	+64%	+$2.08M	0.09%	186
2014 Q3	$3.27M	Buy	45,700 +18,800	+70%	+$1.38M	0.06%	306
2014 Q2	$2M	Buy	26,900 +16,900	+169%	+$1.22M	0.03%	427
2014 Q1	$649K	Buy	+10,000	New	+$646K	0.01%	805

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Integral Derivatives's AZN Position: Q1 2017 in Review

Integral Derivatives sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 4,548 shares — an estimated $265K sold.

Integral Derivatives first reported a position in AZN in Q4 2013 and held it in 5 quarters. The position peaked at $1.77M in Q2 2014. 460 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Integral Derivatives reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 4,548 AstraZeneca shares in Q1 2017, an estimated $265K.
Integral Derivatives first reported a position in AstraZeneca in Q4 2013 and held it in 5 quarters.
Integral Derivatives's AstraZeneca position peaked at $1.77M in Q2 2014.
460 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.